Cargando…
Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug developm...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947521/ https://www.ncbi.nlm.nih.gov/pubmed/29315510 http://dx.doi.org/10.1002/cpt.1010 |